|
|
Post by itellthefuture777 on Jul 14, 2020 15:36:23 GMT -5
Technosphere can also be nebulized...it is multimodal....also..that nebulizer..maybe what they do to get pricing from the Government..but any commercial business is going to streamline down to a disposible inhaler..my guess is..Technosphere is most efficient in any carry the load to lung~
|
|
|
|
Post by agedhippie on Jul 14, 2020 20:44:06 GMT -5
Technosphere can also be nebulized...it is multimodal....also..that nebulizer..maybe what they do to get pricing from the Government..but any commercial business is going to streamline down to a disposible inhaler..my guess is..Technosphere is most efficient in any carry the load to lung~ Last I checked Gilead is a commercial business, especially given how they are pricing remdesvir. They own the nebulizer so they will go with that. It's not like there is competitor for remdesvir in the US. |
|
|
|
Post by itellthefuture777 on Jul 15, 2020 1:16:37 GMT -5
Technosphere can also be nebulized...it is multimodal....also..that nebulizer..maybe what they do to get pricing from the Government..but any commercial business is going to streamline down to a disposible inhaler..my guess is..Technosphere is most efficient in any carry the load to lung~ Last I checked Gilead is a commercial business, especially given how they are pricing remdesvir. They own the nebulizer so they will go with that. It's not like there is competitor for remdesvir in the US. Doesn't make business sense.. |
|
|
|
Post by matt on Jul 15, 2020 11:48:39 GMT -5
Last I checked Gilead is a commercial business, especially given how they are pricing remdesvir. They own the nebulizer so they will go with that. It's not like there is competitor for remdesvir in the US. Doesn't make business sense.. It makes loads of business sense. If you read the dosage instructions, it says this: -Administer by IV infusion only; do not administer as an IM injection.
-Infuse IV over 30 to 120 minutes; after infusion is complete, flush with at least 30 mL of 0.9% saline.
-Do not administer the prepared diluted solution simultaneously with any other medication.
-Treat patients requiring invasive mechanical ventilation and/or ECMO for 10 days.
-Treat patients not requiring invasive mechanical ventilation and/or ECMO for 5 days; if no clinical improvement is shown, may extend treatment for up to 5 additional days (i.e., up to a total of 10 days)
Those are really sick patients and they will be inpatients in a hospital setting whether they are on ventilators / ECMO or otherwise. The gold standard for administering almost any medication is intravenous, and hospitals are likewise familiar with nebulized treatments. If you want a drug to have market acceptance, it needs a delivery system the clinicians are familiar and comfortable with. This is a very potent drug not intended for use beyond the time frames outlined above. If a patient in extremely ill and is in the hospital anyway, there is no commercial incentive to deliver the drug in any other form since essentially 100% of hospital in-patients have IV lines. This is not a safe or simple drug either; 74% of patients experience adverse events, 35% experience serious adverse events which included increased hepatic enzymes, renal impairment, and/or hypotension. It is not a drug a physician is simply going to prescribe to a patient so that they can pick it up at the local Walgreens or CVS - they are going to be closely monitored in the hospital. Insulin is a different beast; it has to be taken several times a day, every day, by ambulatory outpatients that are not gravely ill. TS may have its charms for maintenance medications where the drug is well-characterized, relatively safe, and requires frequent administration. That is not a description that fits any antiviral drug. Just because a drug CAN BE delivered via TS particles does not mean that it should be delivered that way. Keep the discussion focused on how medicine is practiced and drugs that fit into the long-term maintenance category and the discussion will be more productive. |
|
|
|
Post by peppy on Jul 15, 2020 13:23:42 GMT -5
Doesn't make business sense.. It makes loads of business sense. If you read the dosage instructions, it says this: -Administer by IV infusion only; do not administer as an IM injection.
-Infuse IV over 30 to 120 minutes; after infusion is complete, flush with at least 30 mL of 0.9% saline.
-Do not administer the prepared diluted solution simultaneously with any other medication.
-Treat patients requiring invasive mechanical ventilation and/or ECMO for 10 days.
-Treat patients not requiring invasive mechanical ventilation and/or ECMO for 5 days; if no clinical improvement is shown, may extend treatment for up to 5 additional days (i.e., up to a total of 10 days)
Those are really sick patients and they will be inpatients in a hospital setting whether they are on ventilators / ECMO or otherwise. The gold standard for administering almost any medication is intravenous, and hospitals are likewise familiar with nebulized treatments. If you want a drug to have market acceptance, it needs a delivery system the clinicians are familiar and comfortable with. This is a very potent drug not intended for use beyond the time frames outlined above. If a patient in extremely ill and is in the hospital anyway, there is no commercial incentive to deliver the drug in any other form since essentially 100% of hospital in-patients have IV lines. This is not a safe or simple drug either; 74% of patients experience adverse events, 35% experience serious adverse events which included increased hepatic enzymes, renal impairment, and/or hypotension. It is not a drug a physician is simply going to prescribe to a patient so that they can pick it up at the local Walgreens or CVS - they are going to be closely monitored in the hospital. Insulin is a different beast; it has to be taken several times a day, every day, by ambulatory outpatients that are not gravely ill. TS may have its charms for maintenance medications where the drug is well-characterized, relatively safe, and requires frequent administration. That is not a description that fits any antiviral drug. Just because a drug CAN BE delivered via TS particles does not mean that it should be delivered that way. Keep the discussion focused on how medicine is practiced and drugs that fit into the long-term maintenance category and the discussion will be more productive. matt, do you have a dosage amount that? -Infuse IV over 30 to 120 minutes; after infusion is complete, flush with at least 30 mL of 0.9% saline. matt The dreamboat is IV. |
|
|
|
Post by mango on Jul 15, 2020 13:44:31 GMT -5
MannKind’s delivery system mimics intra-arterial administration. 👀
|
|
|
|
Post by jkendra on Jul 15, 2020 13:53:57 GMT -5
They have said that in the longer term, the company is exploring a subcutaneous injection formulation of remdesivir, as well as dry powder versions to be inhaled. Remdesivir cannot be given as a pill because it has a chemical makeup that would degrade in the liver, and the intravenous (IV) formulation is only used by hospitals.
In the short term, Gilead is studying how its existing IV formulation of remdesivir can be diluted for use with a nebulizer - a drug delivery device used to administer medication in the form of a mist inhaled into the lungs.
|
|
|
|
Post by casualinvestor on Jul 15, 2020 14:19:50 GMT -5
For infused drugs, I can see technosphere being a problem because of the speed of absorption. Infusions are longer term delivery and highly diluted. The opposite of what TS does
MNKD is better off focusing on injected/oral drugs where speed of action is important, like migraines
|
|
|
|
Post by peppy on Jul 15, 2020 14:24:20 GMT -5
For infused drugs, I can see technosphere being a problem because of the speed of absorption. Infusions are longer term delivery and highly diluted. The opposite of what TS does MNKD is better off focusing on injected/oral drugs where speed of action is important, like migraines in this case, COVID 19, the problem is In the alveoli. just sayin. dosage? |
|
|
|
Post by casualinvestor on Jul 15, 2020 15:30:35 GMT -5
Dosage is a couple pages back mnkd.proboards.com/post/204535/threadYou probably know more about infusions than I do. But my impression is that too high of a concentration of some infused drugs is bad for healthy cells, no matter where they are. IE, cancer killing drugs. That may not be the case here if they are looking at sub-q delivery. But I thought we had already worked it out in another thread that 200mg was too much for technosphere? |
|
|
|
Post by peppy on Jul 15, 2020 18:10:18 GMT -5
Dosage is a couple pages back mnkd.proboards.com/post/204535/threadYou probably know more about infusions than I do. But my impression is that too high of a concentration of some infused drugs is bad for healthy cells, no matter where they are. IE, cancer killing drugs. That may not be the case here if they are looking at sub-q delivery. But I thought we had already worked it out in another thread that 200mg was too much for technosphere? I am sorry casual, yes. |
|
|
|
Post by jkendra on Jul 29, 2020 18:06:23 GMT -5
FF Pharmaceuticals Comments on Research on the Re-formulation of Remdesivir to a Dry Powder Form for COVID-19 Antiviral Treatment
Scientists at The University of Texas at Austin report on the use of Thin Film Freezing technology to deliver remdesivir through dry powder inhalation
July 29, 2020 09:33 AM Eastern Daylight Time
AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today commented on the initial results of research evaluating the development of remdesivir as a dry powder for inhalation by Thin Film Freezing. Findings of the study conducted by a team of researchers at the University of Texas at Austin’s Division of Molecular Pharmaceutics and Drug Delivery, led by Robert O. (Bill) Williams III, the inventor of the TFF technology, was published yesterday as a preprint in bioRxiv.
The research team developed inhaled forms of remdesivir for protecting and treating the respiratory mode of infection, including an amorphous brittle matrix powder made by Thin Film Freezing.
“We are very pleased to report on the efforts of Dr. Williams and his team, who in the span of less than a month and responding to the societal need caused by the global pandemic, worked tirelessly to reformulate what may be one of the most important new COVID-19 therapeutics into a form that has the potential to make treatment more potent, easier to administer and more broadly available” said Glenn Mattes, President and CEO of TFF Pharmaceuticals
“If patients can avoid a hospital visit to begin remdesivir treatment, it can lessen the current strains on our health system, lower cost and provide fewer points of contact with those who are still contagious,” Williams said. “More widely available early stage intervention methods could significantly lessen symptoms before they become potentially life-threatening, providing more hospital beds and ventilators to those who need them the most.”
“It’s important to note that remdesivir is the proprietary product of Gilead and, at this time, TFF has no agreements with Gilead concerning a collaboration built around remdesivir and our TFF platform,” continued Mattes. “And while we intend to pursue discussions with Gilead regarding the results of Dr. Williams’ formulation work, there can be no assurance that this effort would result in a collaboration between our companies. We are very encouraged and proud of the continued work done by Dr. Williams’ team as it further demonstrates the ability of our Thin Film Freezing platform to adapt to a variety of compounds that may be poorly water soluble and thus may be challenging to deliver therapeutically.”
“TFF is continuing to pursue a number of other potential opportunities and partnerships for our thin film freezing platform technology. We are, for example, evaluating biologics, oligonucleotides, small molecules, vaccines, and other therapeutics for COVID-19 and additional indications,” continued Mattes. “This also includes formulation work on repurposing niclosamide, an existing oral anthelminthic drug, as a therapeutic option to treat Covid-19.”
|
|
|
|
Post by goyocafe on Jul 29, 2020 19:23:52 GMT -5
With a 20 year head start, and this is where MNKD ends up.
|
|
|
|
Post by itellthefuture777 on Jul 30, 2020 22:16:27 GMT -5
Mannkind dry powder manufacturing capability and capacity could easily find itself under the defense production act like Kodac..(speculating)..hmm
|
|
